253 related articles for article (PubMed ID: 31385425)
1. IDegLira improves patient-reported outcomes while using a simple regimen with fewer injections and dose adjustments compared with basal-bolus therapy.
Miller E; Doshi A; Grøn R; Jódar E; Őrsy P; Ranthe MF; Sugimoto D; Tentolouris N; Viljoen A; Billings LK
Diabetes Obes Metab; 2019 Dec; 21(12):2643-2650. PubMed ID: 31385425
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically Relevant Treatment Targets.
Cannon AJ; Bargiota A; Billings L; Hunt B; Leiter LA; Malkin S; Mocarski M; Ranthe MF; Schiffman A; Doshi A
J Manag Care Spec Pharm; 2020 Feb; 26(2):143-153. PubMed ID: 31856636
[TBL] [Abstract][Full Text] [Related]
3. Insulin degludec/liraglutide (IDegLira) maintains glycaemic control and improves clinical outcomes, regardless of pre-trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin.
Meneghini L; Doshi A; Gouet D; Vilsbøll T; Begtrup K; Őrsy P; Ranthe MF; Lingvay I
Diabet Med; 2020 Feb; 37(2):267-276. PubMed ID: 31705547
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial.
Billings LK; Doshi A; Gouet D; Oviedo A; Rodbard HW; Tentolouris N; Grøn R; Halladin N; Jodar E
Diabetes Care; 2018 May; 41(5):1009-1016. PubMed ID: 29483185
[TBL] [Abstract][Full Text] [Related]
5. Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial.
Aroda VR; González-Galvez G; Grøn R; Halladin N; Haluzík M; Jermendy G; Kok A; Őrsy P; Sabbah M; Sesti G; Silver R
Lancet Diabetes Endocrinol; 2019 Aug; 7(8):596-605. PubMed ID: 31189519
[TBL] [Abstract][Full Text] [Related]
6. The management of type 2 diabetes with fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy (insulin glargine U100 plus insulin aspart): A short-term cost-effectiveness analysis in the UK setting.
Drummond R; Malkin S; Du Preez M; Lee XY; Hunt B
Diabetes Obes Metab; 2018 Oct; 20(10):2371-2378. PubMed ID: 29797389
[TBL] [Abstract][Full Text] [Related]
7. Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial.
Lingvay I; Harris S; Jaeckel E; Chandarana K; Ranthe MF; Jódar E
Diabetes Obes Metab; 2018 Jan; 20(1):200-205. PubMed ID: 28643425
[TBL] [Abstract][Full Text] [Related]
8. Ideglira is Associated With Improved Short-Term Clinical Outcomes and Cost Savings Compared with Insulin Glargine U100 Plus Insulin Aspart in the U.S.
Dempsey M; Mocarski M; Langer J; Hunt B
Endocr Pract; 2018 Sep; 24(9):796-804. PubMed ID: 30308134
[TBL] [Abstract][Full Text] [Related]
9. The Benefit of Insulin Degludec/Liraglutide (IDegLira) Compared With Basal-Bolus Insulin Therapy is Consistent Across Participant Subgroups With Type 2 Diabetes in the DUAL VII Randomized Trial.
Billings LK; Agner BFR; Altuntas Y; Grøn R; Halladin N; Klonoff DC; Tentolouris N; Jódar E
J Diabetes Sci Technol; 2021 May; 15(3):636-645. PubMed ID: 32107930
[TBL] [Abstract][Full Text] [Related]
10. Fixed-ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin.
Vilsbøll T; Blevins TC; Jodar E; Poulter N; Tentolouris N; Ross Agner BF; Lehmann L; Leiter LA
Diabetes Obes Metab; 2019 Jun; 21(6):1506-1512. PubMed ID: 30785655
[TBL] [Abstract][Full Text] [Related]
11. Superior HbA1c control with the fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with a maximum dose of 50 units of insulin degludec in Japanese individuals with type 2 diabetes in a phase 3, double-blind, randomized trial.
Watada H; Kaneko S; Komatsu M; Agner BR; Nishida T; Ranthe M; Nakamura J
Diabetes Obes Metab; 2019 Dec; 21(12):2694-2703. PubMed ID: 31423685
[TBL] [Abstract][Full Text] [Related]
12. Superior efficacy with a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin-naïve Japanese patients with type 2 diabetes in a phase 3, open-label, randomized trial.
Kaku K; Araki E; Tanizawa Y; Ross Agner B; Nishida T; Ranthe M; Inagaki N
Diabetes Obes Metab; 2019 Dec; 21(12):2674-2683. PubMed ID: 31407845
[TBL] [Abstract][Full Text] [Related]
13. Cost Effectiveness of IDegLira vs. Alternative Basal Insulin Intensification Therapies in Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in a UK Setting.
Davies MJ; Glah D; Chubb B; Konidaris G; McEwan P
Pharmacoeconomics; 2016 Sep; 34(9):953-66. PubMed ID: 27438706
[TBL] [Abstract][Full Text] [Related]
14. An indirect treatment comparison of the efficacy of insulin degludec/liraglutide (IDegLira) and insulin glargine/lixisenatide (iGlarLixi) in patients with type 2 diabetes uncontrolled on basal insulin.
Evans M; Billings LK; Håkan-Bloch J; Slothuus U; Abrahamsen TJ; Andersen A; Jansen JP
J Med Econ; 2018 Apr; 21(4):340-347. PubMed ID: 29164973
[TBL] [Abstract][Full Text] [Related]
15. Benefits of combination of insulin degludec and liraglutide are independent of baseline glycated haemoglobin level and duration of type 2 diabetes.
Rodbard HW; Buse JB; Woo V; Vilsbøll T; Langbakke IH; Kvist K; Gough SC
Diabetes Obes Metab; 2016 Jan; 18(1):40-8. PubMed ID: 26343931
[TBL] [Abstract][Full Text] [Related]
16. Use and effectiveness of a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) in a real-world population with type 2 diabetes: Results from a European, multicentre, retrospective chart review study.
Price H; Blüher M; Prager R; Phan TM; Thorsted BL; Schultes B;
Diabetes Obes Metab; 2018 Apr; 20(4):954-962. PubMed ID: 29205856
[TBL] [Abstract][Full Text] [Related]
17. Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add-on to sodium-glucose co-transporter-2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes.
Philis-Tsimikas A; Billings LK; Busch R; Portillo CM; Sahay R; Halladin N; Eggert S; Begtrup K; Harris S
Diabetes Obes Metab; 2019 Jun; 21(6):1399-1408. PubMed ID: 30761720
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes.
Gough SC; Bode B; Woo V; Rodbard HW; Linjawi S; Poulsen P; Damgaard LH; Buse JB;
Lancet Diabetes Endocrinol; 2014 Nov; 2(11):885-93. PubMed ID: 25190523
[TBL] [Abstract][Full Text] [Related]
19. Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden.
Ericsson Å; Lundqvist A
Appl Health Econ Health Policy; 2017 Apr; 15(2):237-248. PubMed ID: 28063135
[TBL] [Abstract][Full Text] [Related]
20. Benefits of insulin degludec/liraglutide are maintained even in patients discontinuing sulphonylureas or dipeptidyl peptidase-4 inhibitors upon initiation of degludec/liraglutide therapy: A post hoc analysis of the DUAL II and DUAL IX trials.
Janez A; Őrsy P; Stachlewska K; Salvesen-Sykes K; Billings LK; Philis-Tsimikas A
Diabetes Obes Metab; 2020 Apr; 22(4):658-668. PubMed ID: 31858673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]